MX2018010983A - Derivado de 3-desoxi y composiciones farmaceuticas del mismo. - Google Patents
Derivado de 3-desoxi y composiciones farmaceuticas del mismo.Info
- Publication number
- MX2018010983A MX2018010983A MX2018010983A MX2018010983A MX2018010983A MX 2018010983 A MX2018010983 A MX 2018010983A MX 2018010983 A MX2018010983 A MX 2018010983A MX 2018010983 A MX2018010983 A MX 2018010983A MX 2018010983 A MX2018010983 A MX 2018010983A
- Authority
- MX
- Mexico
- Prior art keywords
- desoxy
- derived
- same
- pharmaceutical compositions
- compound
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000012190 activator Substances 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 229940125904 compound 1 Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Cephalosporin Compounds (AREA)
Abstract
La presente solicitud proporciona el Compuesto 1: (ver Fórmula) o una sal farmacéuticamente aceptable o conjugado de aminoácidos del mismo. La presente invención se refiere a un activador de FXR y a métodos de fabricación y uso del compuesto.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662306914P | 2016-03-11 | 2016-03-11 | |
| PCT/US2017/021194 WO2017156024A1 (en) | 2016-03-11 | 2017-03-07 | 3-desoxy derivative and pharmaceutical compositions thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018010983A true MX2018010983A (es) | 2019-01-21 |
| MX384800B MX384800B (es) | 2025-03-14 |
Family
ID=59787771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018010983A MX384800B (es) | 2016-03-11 | 2017-03-07 | Derivado de 3-desoxi y composiciones farmaceuticas del mismo. |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US10815267B2 (es) |
| EP (1) | EP3426348B1 (es) |
| JP (1) | JP6892457B2 (es) |
| KR (1) | KR102359191B1 (es) |
| CN (1) | CN108883305B (es) |
| AR (1) | AR107864A1 (es) |
| AU (1) | AU2017229481B2 (es) |
| BR (1) | BR112018068278B1 (es) |
| CA (1) | CA3016875C (es) |
| EA (1) | EA038632B1 (es) |
| ES (1) | ES2874682T3 (es) |
| IL (1) | IL261548B (es) |
| MX (1) | MX384800B (es) |
| PH (1) | PH12018501956A1 (es) |
| PL (1) | PL3426348T3 (es) |
| PT (1) | PT3426348T (es) |
| SG (1) | SG11201807784SA (es) |
| SI (1) | SI3426348T1 (es) |
| TW (1) | TWI772289B (es) |
| WO (1) | WO2017156024A1 (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1243930A1 (zh) | 2014-11-06 | 2018-07-27 | 英安塔制药有限公司 | 作爲fxr/tgr5激动剂的胆汁酸类似物和其使用方法 |
| US11578097B2 (en) | 2014-11-26 | 2023-02-14 | Enanta Pharmaceuticals, Inc. | Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof |
| US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| CA2968404A1 (en) | 2014-11-26 | 2016-06-02 | Enanta Pharmaceuticals, Inc. | Bile acid analogs as fxr/tgr5 agonists and methods of use thereof |
| WO2016130809A1 (en) | 2015-02-11 | 2016-08-18 | Enanta Pharmaceuticals, Inc. | Bile acid analogs as fxr/tgr5 agonists and methods of use thereof |
| SG11201707263XA (en) | 2015-03-31 | 2017-10-30 | Enanta Pharm Inc | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
| UA123948C2 (uk) * | 2015-10-07 | 2021-06-30 | Інтерсепт Фармасьютікалз, Інк. | Модулятори фарнезоїдного х-рецептора |
| US10364267B2 (en) | 2016-02-23 | 2019-07-30 | Enanta Pharmaceuticals, Inc. | Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| WO2017147174A1 (en) | 2016-02-23 | 2017-08-31 | Enanta Pharmaceuticals, Inc. | Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof |
| WO2017147137A1 (en) | 2016-02-23 | 2017-08-31 | Enanta Pharmaceuticals, Inc. | Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof |
| ES2874682T3 (es) | 2016-03-11 | 2021-11-05 | Intercept Pharmaceuticals Inc | Derivados de 3-desoxi y composiciones farmacéuticas de los mismos |
| AU2017368069B2 (en) | 2016-11-29 | 2021-07-08 | Enanta Pharmaceuticals, Inc. | Process for preparation of sulfonylurea bile acid derivatives |
| WO2018152171A1 (en) | 2017-02-14 | 2018-08-23 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as fxr agonists and methods of use thereof |
| MX388300B (es) | 2017-04-07 | 2025-03-19 | Enanta Pharm Inc | Proceso para la preparación de derivados de ácidos biliares de sulfonil carbamato |
| GB201812382D0 (en) | 2018-07-30 | 2018-09-12 | Nzp Uk Ltd | Compounds |
| US20230165853A1 (en) * | 2021-01-14 | 2023-06-01 | Enyo Pharma | Method for treating chronic kidney diseases |
| WO2023288123A1 (en) | 2021-07-16 | 2023-01-19 | Interecept Pharmaceuticals, Inc. | Methods and intermediates for the preparation of 3.alpha.,7.alpha.,11.beta.-trihydroxy-6.alpha.-ethyl-5.beta.-cholan-24-oic acid |
| JP2025513289A (ja) * | 2022-04-21 | 2025-04-24 | インターセプト ファーマシューティカルズ， インコーポレイテッド | ファルネソイドｘ受容体アゴニストの使用 |
| WO2024097247A1 (en) * | 2022-10-31 | 2024-05-10 | Intercept Pharmaceuticals, Inc. | Uses of farnesoid x receptor agonists |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1734970B1 (en) * | 2004-03-12 | 2014-12-31 | Intercept Pharmaceuticals, Inc. | Treatment of fibrosis using fxr ligands |
| WO2012047495A2 (en) | 2010-09-27 | 2012-04-12 | Kythera Biopharmaceuticals, Inc. | Methods for preparing synthetic bile acids and compositions comprising the same |
| KR101922164B1 (ko) | 2011-12-29 | 2019-02-13 | 노보 노르디스크 에이/에스 | 비-단백질원 아미노산을 포함하는 디펩티드 |
| ES2843737T3 (es) * | 2013-05-14 | 2021-07-20 | Intercept Pharmaceuticals Inc | Derivados sustituidos con 11-hidroxilo-6 de ácidos biliares y conjugados de aminoácidos de los mismos como moduladores de receptor de farnesoide X |
| RS59910B1 (sr) * | 2014-05-29 | 2020-03-31 | Bar Pharmaceuticals S R L | Derivati holana za upotrebu u lečenju i/ili prevenciji fxr i tgr5/gpbar1 posredovanih bolesti |
| CN108137643A (zh) * | 2015-08-07 | 2018-06-08 | 英特塞普特医药品公司 | 制备胆汁酸及其衍生物的方法 |
| ES2874682T3 (es) | 2016-03-11 | 2021-11-05 | Intercept Pharmaceuticals Inc | Derivados de 3-desoxi y composiciones farmacéuticas de los mismos |
-
2017
- 2017-03-07 ES ES17763922T patent/ES2874682T3/es active Active
- 2017-03-07 EA EA201892007A patent/EA038632B1/ru unknown
- 2017-03-07 PT PT177639226T patent/PT3426348T/pt unknown
- 2017-03-07 EP EP17763922.6A patent/EP3426348B1/en active Active
- 2017-03-07 BR BR112018068278-0A patent/BR112018068278B1/pt active IP Right Grant
- 2017-03-07 SG SG11201807784SA patent/SG11201807784SA/en unknown
- 2017-03-07 PL PL17763922T patent/PL3426348T3/pl unknown
- 2017-03-07 JP JP2018547355A patent/JP6892457B2/ja active Active
- 2017-03-07 CN CN201780018432.7A patent/CN108883305B/zh active Active
- 2017-03-07 AU AU2017229481A patent/AU2017229481B2/en active Active
- 2017-03-07 SI SI201730776T patent/SI3426348T1/sl unknown
- 2017-03-07 KR KR1020187028967A patent/KR102359191B1/ko active Active
- 2017-03-07 MX MX2018010983A patent/MX384800B/es unknown
- 2017-03-07 WO PCT/US2017/021194 patent/WO2017156024A1/en not_active Ceased
- 2017-03-07 US US15/451,818 patent/US10815267B2/en active Active
- 2017-03-07 CA CA3016875A patent/CA3016875C/en active Active
- 2017-03-09 TW TW106107817A patent/TWI772289B/zh active
- 2017-03-13 AR ARP170100619A patent/AR107864A1/es unknown
-
2018
- 2018-09-03 IL IL261548A patent/IL261548B/en active IP Right Grant
- 2018-09-06 US US16/124,122 patent/US20190002493A1/en not_active Abandoned
- 2018-09-11 PH PH12018501956A patent/PH12018501956A1/en unknown
-
2020
- 2020-09-18 US US17/025,475 patent/US11319337B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018010983A (es) | Derivado de 3-desoxi y composiciones farmaceuticas del mismo. | |
| JOP20200122A1 (ar) | مركبات مفيدة لتثبيط cdk7 | |
| SA518400660B1 (ar) | مركبات بيرميدين-2-يل أمينو -1h- بيرازول في صورة مثبطات لاستخدامها في علاج الاضطرابات التنكسية العصبيةlrrk2 | |
| MX391812B (es) | Agonista fxr derivado de esteroides. | |
| EA201891083A1 (ru) | Составы антител к cd38 для подкожного введения и их применение | |
| PH12018500777A1 (en) | Farnesoid x receptor modulators | |
| MX2019009861A (es) | Composiciones farmaceuticas de un derivado de acido biliar y microbioma y usos de las mismas. | |
| EA201691242A1 (ru) | Фармацевтические композиции, содержащие azd9291 | |
| EA201690930A1 (ru) | Композиции и способы модуляции фарнезоидных х-рецепторов | |
| EA202090688A1 (ru) | Бис-амидные соединения, активирующие саркомер, и варианты их применения | |
| MX381487B (es) | Ciertos inhibidores de la proteina quinasa. | |
| EA201992116A1 (ru) | Фармацевтические составы флороглюцинола и триметилфлороглюцинола | |
| EA201891644A1 (ru) | Антибактериальные соединения и их применение | |
| EA202191114A1 (ru) | Производные пиридинилсульфонамида, фармацевтические композиции и их применение | |
| CL2019001053A1 (es) | Formulaciones farmacéuticas y métodos para prepararlas. | |
| EA201790046A1 (ru) | Бензоксазиноновые амиды в качестве модуляторов минералокортикоидного рецептора | |
| EA201791432A1 (ru) | Композиции на основе пролекарства монометилфумарата | |
| EA201791992A1 (ru) | Ингибиторы грелин-o-ацилтрансферазы | |
| EA201692300A1 (ru) | Производные карбоксамида | |
| CY1123728T1 (el) | (2r,4r)-5-(5'-χλωρο-2'-φθοροδιφαινυλ-4-υλ) -2-υδροξυ-4- [(5-μεθυλοξαζολο-2-καρβονυλ) αμινο] πεντανοϊκο οξυ | |
| EA201791600A1 (ru) | Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора | |
| EA201792000A1 (ru) | Ингибиторы грелин-o-ацилтрансферазы | |
| CY1123877T1 (el) | Μορφες στερεας καταστασης αλατων νιλοτινιμπης | |
| MX388592B (es) | Compuestos y metodos terapeuticos. | |
| EA201691796A1 (ru) | П-замещенные асимметричные мочевины и их применение в медицине |